Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The new facility is expected to manufacture Abraxane, the first solvent-free chemotherapy treatment option for metastatic breast cancer
Subscribe to our email newsletter
Abraxis Health, a fully-integrated personalised healthcare division of Abraxis BioScience, has dedicated its new manufacturing facility in Phoenix, Arizona. The biopharma manufacturing plant represents a $70m investment by LA-based Abraxis, and is expected to create up to 200 high tech jobs.
The company said that the new facility will manufacture Abraxane, the first solvent-free chemotherapy treatment option for metastatic breast cancer, which was developed using Abraxis BioScience’s proprietary nab technology platform. The company added that it has multiple agreements in place for the development of novel, insoluble compounds using the nanobiologics technology employed at the Phoenix plant.
Reportedly, the facility will be a protein nanobiologics manufacturing plant, with annual production capacity of over 10m units, and the capability to expand to 20m units, suitable for worldwide distribution.
Patrick Soon-Shiong, founder and chairman of Abraxis, said: “The outlook for Abraxis is immensely encouraging. As we continue to grow, these new premises in Phoenix will become the flagship manufacturing facility for our cutting edge technology.”
Terry Goddard, attorney general of the State, said: “Arizona is proud to welcome Abraxis as a powerful new addition to our growing life sciences sector.”
Phil Gordon, Mayor of Phoenix Arizona, said: This is great news for Phoenix. We are delighted that Abraxis has chosen our city for this state of the art nanotech manufacturing plant, bringing highly skilled jobs and a welcome boost for our economy.”